Abstract
Introduction: In Honduras on March 12, 2020, the first case of COVID-19 caused by the SARS-CoV-2 was reported. From that moment on, a series of measures were adopted to slow down contact throughout the country. By June 2020, cases are reported across the whole country. With the objective of identifying the presence and circulation of SARS-CoV-2, characterizing and identifying suggestive symptoms of COVID-19 in the population, the present study was carried out. Methodology: A descriptive cross-sectional study was carried out, using a quantitative and qualitative approach, using the LQAS sampling method. The study population was the inhabitants of the identified municipalities, with no current circulation data for SARS-CoV-2 or the municipalities whose last confirmed case was 21 days ago. The data was collected through an electronic survey, it was possible to apply rapid antibody detection tests (IgG and IgM). Results: 792 people from 41 municipalities of the country were surveyed and tested. Positivity of contact was found in 6.2% (49/792). Of these, 55.1% (27/49) are men. 61.2% (30/49) are between 20 and 49 years old. The clinical symptoms found were fever, decreased appetite, respiratory distress, and loss of taste and smell, the 49.2% (32/49) without symptoms. Conclusions: virus circulation was demonstrated in the population of municipalities in which no cases were officially reported and after 96 days of the first confirmed case in the country. Detection of virus-specific antibodies could be important in surveys for asymptomatic infection in areas where contact is expected.
References
Decreto Ejecutivo N° PCM-005-2020 (2020). Recuperado de https://www.tsc.gob.hn/web/leyes/Decreto- 33-2020.pdf
Decreto Ejecutivo, N° PCM-021-2020 (2020). Recuperado de https://presidencia.gob.hn/index.php/sala-de-prensa/7016-decreto-ejecutivo-numero-pcm-021-2020
Despacho de Comunicaciones y Estrategia Presidencial. (2020a). Coronavirus COVID-19 En Honduras. Recuperado de https://covid19honduras.org/
Despacho de Comunicaciones y Estrategia Presidencial. (2020b). Recibe el alta la paciente cero, primer caso de COVID-19 en Honduras. Recuperado de https://covid19honduras.org/?q=paciente-cero-recibe-el-alta
Gao, J., Huang, X., Gu, H., Lou, L. y Xu, Z. (2020). Predictive criteria of severe cases in COVID-19 patients of early stage. Research Square, [Preprint]. DOI: https://doi.org/10.21203/rs.3.rs-39161/v1
Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J. y Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Medical Research, 7(1), 11. Doi: https://doi.org/10.1186/s40779-020-00240-0
Hou, H., Wang, T., Zhang, B., Luo, Y., Mao, L., Wang, F. y Sun, Z. (2020). Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clinical & Translational Immunology, 9(5), e01136. Doi: https://doi.org/10.1002/cti2.1136
John Hopkins Center for Health Security. (2020). Serology-based tests for COVID-19 [Sitio web]. Recuperado de https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html
Klein, S. L. y Flanagan, K. L. (2016). Sex differences in immune responses. Nature reviews Immunology, 16(10), 626–638. Doi: https://doi.org/10.1038/nri.2016.90
Organización Mundial de la Salud. (2020). Neumonía de causa desconocida – China: Brotes epidémicos. Recuperado de https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/es/
Ramírez, P. A., Valencia, Y. E., Carrillo, C. Q., Ayala, E. V., Delgado, J. d. L. y Cruz, A. P. (2020). Pruebas diagnósticas para la COVID-19: la importancia del antes y el después. Horizonte MéDico (Lima), 20(2). Recuperado de http://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/1231
Sethuraman, N., Jeremiah, S. S. y Ryo, A. (2020). Interpreting Diagnostic Tests for SARS-CoV-2. JAMA, 323(22). Doi: https://doi.org/10.1001/jama.2020.8259
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H. y Guessous, I. (2020). Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. The Lancet, 396(10247), 313-319. Doi: https://doi.org/10.1016/S0140-6736(20)31304-0
Sun, P., Lu, X., Xu, C., Sun, W. y Pan, B. (2020). Understanding of COVID-19 based on current evidence. Journal of medical virology, 92(6), 548–551. Doi: https://doi.org/10.1002/jmv.25722
Valadez, J., Weiss, W., Leburg, C. y Davis, R. (2002). LQAS Participant's Manual 2007 - CORE Group. Recuperado de https://www.yumpu.com/en/document/read/22874006/lqas-participants-manual-2007-core-group
World Health Organization. (2020). Coronavirus Disease (COVID-19) Dashboard. Recuperado de https://covid19.who.int/?gclid=Cj0KCQjwvIT5BRCqARIsAAwwD-SYDaVY_b6viVzl43hDLUTB2Kkr0_ZcdeCiJab7ibeCv4sRtfowMkgaAoYSEALw_wcB
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Zhou, Y. (2020). Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International journal of infectious diseases, 94, 91–95. Doi: https://doi.org/10.1016/j.ijid.2020.03.017
Yin, Y. y Wunderink, R. (2018). MERS, SARS and other coronaviruses as causes of pneumonia. Respirology, 23(2), 130–137. Doi: https://doi.org/10.1111/resp.13196